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Abstract: Background: Nasopharyngeal malignancy is the first most common malignancy amongst in ear, nose and throat. 
Incidence rate was 4.7 per 100.000 or 7.000-8.000 cases per year and most of carcinoma is arising from the epithelial cells. 
Objective: To analyze the VEGF gene variations at +405 C/G and -460 T/C with VEGFR (Flt-4) and LMP-1 tissues expression 
of nasopharyngeal carcinoma (NPC). Methods: A cross sectional study was carried out with explorative approached at several 
teaching hospitals in Makassar by Hasanuddin University Research Centre and Eijkman Institute for Molecular Biology on a 
one-year period, from July 2006 through August 2007. The analysis covered from 90 samples of blood and 45 samples of 
nasopharynx tissue, consisting of 45 patients for both of the NPC and without NPC as a control. Genomic DNA was extracted 
from peripheral blood and analyzed by PCR and direct DNA sequencing method for identifying the location of VEGF gene 
mutation and immunohistochemical expression of VEGFR (Flt-4) and LMP-1 were performed in 45 NPC biopsy samples with 
avidin-biotin method. Results: The frequencies of +405 C/G and -460 T/C were about 50%, with higher in +405 C/G (hot spot), 
mostly genotype variant was heterozygote (CG). Our results confirmed that untranslated and promoter region of VEGF gene 
were higher polymorphic. GC and CC haplotype at +405 C/G and -460 T/C of VEGF gene more susceptible to NPC compared 
with CT haplotype but no statistical significant. Conclusion: There were no relationships between genotype distribution and 
allele frequencies at VEGF gene +405 C/G, -460 T/C and -457 T/C with the NPC risk factors. 
Keywords: Nasopharyngeal Carcinoma (NPC), Vascular Endothelial Growth Factor (VEGF),  
Latent Membrane Protein (LMP-1) 
 
1. Introduction 
The highest incidence of nasopharyngeal malignancy is in 
Guang Dong Province, China, which are 40–50 cases per 
100.000 populations per year. Then it is followed by, Eskimo, 
Tunisia, Philippines, Malaysia, Algeria and Indonesia. It is 
rare in whites, Japan, and India. From nasopharyngeal 
carcinoma profile data report in Hasanuddin University 
teaching hospital, Makassar from January 2000 to June 2007, 
it was reported that nasopharyngeal carcinoma (NPOC) 
accounts 33% of all malignancy in ear, nose, and throat with 
highest incidence in 4 and 5 decades age groups, male and 
female proportion; 2-3:1, and most of the histopathology type 
is anaplastic carcinoma, with the high tendency of 
metastasis.
1
 NPC is often undetected in the early stage 
because the variations of symptoms and difficulty of 
examining the nasopharynx; therefore, the mortality rate is 
high, which the patients seek medical care in stage III or IV 
with 10 years survival rate about 10%.
2, 3, 4 
One of the NPC treatments is radiotherapy, which is the 
main modality; chemotherapy and resection depend on the 
stage and each hospital protocol. With the low survival rate, 
patients with late stadium often treated with chemotherapy 
adjuvant, concomitant, or neo adjuvant with radiotherapy of 
sandwich fashion, but the result is not satisfying.
4-9 
One of the risk factor for somatic cell malignancy process 
is gene mutation. Gene mutation can be caused by viral 
infection, radiation, and carcinogenic substance. Epstein - 
Barr virus (EBV) is a Herpesviridae family, with gamma 
Herpes virus subfamily, genera lymphocryptovirus. EBV 
could be detected with serology test, cell culture, and DNA 
technology. There are two types of EBV, type 1 and 2. Both 
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of this type could be found in most of human oropharynx. 
EBV type 1 is more often found in industrial countries, and 
type 2 is more often found in Africa and developing 
countries.
9, 10, 11 
Latent Membrane Protein (LMP-1) product is a integral 
membrane protein (onkoprotein), was found in 95.6% of 
NPC patients.
12
 EBV LMP-1 induce COX-2 (cyclooxygenase) 
expresion from NFkB through CTAR1 and CTAR2 (carboxyl 
terminal activation region) in nasopharyngeal epitelial cells, 
induce prostaglandine E2 expresion and increase the 
production of vascular endothelial growth factor (VEGF), 
which have a role in NPC angiogenesis. 
Certain polmorphisms have been reported in VEGF genes 
(+405 C/G and -460 T/C) in lung cancer, that is linked to 
VEGF protein variations.
13, 14
 Knowing the VEGF gene DNA 
sequences, it is expected to know about the individual 
clinical manifestation of NPC. There is a meaningful 
relationship between VEGF gene variations on +405 C/G and 
-460 T/C alleles in squamous cell cancer
13, 14, 15
; therefore in 
this study, we want to assess the VEGF gene variations on 
+405 C/G and -460 T/C alleles with stages, histopathology of 
NPC with different ethnic groups, and if there is a new 
genetic variation in the NPC patients in Makassar. 
2. Methods 
This study was a cross-sectional study with explorative 
approach and case-control by analytic. This study conducted 
in Teaching hospitals in Makassar, from July 2006 to August 
2007. The samples were NPC patients who seek care in the 
teaching hospitals, and met the inclusion criteria, and were 
taken using non-random sampling. Amount of the cases were 
45 and controls were 45. 
Staining procedure was the 5 µm thick paraffin block, 
placed under pre cleaned white glass with poly L lysine 
coated, then incubated for one night. After the samples were 
deparaffinized, it is washed using Phosphat Buffer Saline 
(PBS) and citric buffer, then blocking normal serum (Ultra V 
Block) was added. Then, primary anti LMP-1 antibody (Novo 
Costra) and anti VEGF-R(Flt-4) (Lab. Viscon) were added, 
and stored in refrigerator for 24 hours. Next, the samples 
were washed by PBS, and were added secondary antibody 
(Biotinylated Goat Anti Polyvalent), incubated, were washed 
using PBS, and were added streptavidin peroxidase, and 
incubated in room temperature. Next, it is washed again 
using PBS, were added DAB (Diamino benzidine), and were 
washed using H2O, and stained using hematoxillin-eosin. 
LMP-1 positive expression is seen as brownish granules in 
membrane and cytoplasm, and VEGF-R is seen as brownish 
granules in cell cytoplasm. The expression count was done 
under binoculary microscope with 100-200 times 
magnification and was choosen randomly and counted in 
100-200 cells. 
3. Interpretation 
LMP-1 (semi quantitative) 
0 : negative, +1 : weak (<10% expression) 
+2 : moderate (10% - 25%) +3 : strong (expression>25%) 
VEGF- R (Flt-4) (semi quantitative) 
0 : negative, +1 : <25% expression 
+2 : 26% - 50% expression +3 : 51% - 75% expression 
+4 : >75% expression 
VEGF DNA extraction was using Chelex method, VEGF 
DNA amplication: 
Primer : 
Forward : -460F = 5’- CCT CTT TAG CCA GAG CCG 
GGG -3’ 
+405F = 5’- CGA CGG CTT GGG GAG ATT GC-3’ 
Reverse : -460R = 5’- TGG CCT TCT CCC CGC TCC 
GAC-3’ 
+405R= 5’- GGG CGG TGT CTG TCT GTC TG-3’ 
After the PCR process, the samples were visualized under 
UV light. In the sequencing, PCR products were placed in 
ABI-prism, and compared with human VEGF gene database. 
Univariate analysis for categories data with nominal and 
ordinal scales, were using Chi square test likelihood, Chi 
square test Spearman and Odds Ratio (OR). Bivariate 
analysis was using Spearman correlation. 
4. Results 
In July 2006 to August 2007 period, it has been done, a 
research for VEGF gene polymorphism in NPC based on 
genotype distribution and its haplotype on +405 C/G, 
untranslated part and -460 T/C which is VEGF gene 
promoter in NPC. 
On 90 samples, which was consisted of 45 NPC cases and 
45 healthy controls. Immunohistochemistry test was done for 
evaluating VEGFR and LMP-1 expression in cases only, 
because the control group was not undergone biopsy 
evaluation. We did not evaluate RFLP (Retriction Fragment 
Length Polymorphism) because enzyme restriction; BsaH I 
and BsmFI could not be obtained commercially. So, We did 
direct sequencing from 3ml Cubiti vein blood sample on all 
samples. 
4.1. Sample Characteristics 
From the sample characterictics, we found the NPC 
patients age mean is 45.80 ± 13.70 year old. Male are 38 
(84.44%) and female were 7 (15.56%). There are two ethnics 
in our study, Buginese consisted of 21 patients (46.67%) and 
Makassarese consisted 12 (26.67%). From the control group, 
the age mean is 39.22 ± 12.53 years. 
Primary complaint from NPC patients were bloodstained 
discharge or epistaxis are 16 (35.56%) followed by 9 
cephalgia (20%). The chief complaint was neck mass 24 
(53.33%) and nasal obstruction 10 (22.22%). In early stage, 
we found untypical symptoms, such as unilateral hearing loss, 
tinnitus, and aural fullness. 
4.2. PCR Result 
We did PCR test, and succeed amplifing DNA target with 
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280 bp, with VEGF gene mutation on allele +405 C/G inside 
(Figure 1.) 
 
Figure 1. DNA VEGF allele +405 C/G PCR Product Electrophoresis. Lane 
1 : marker 2,3,4 and 5 represents sample with 280 bp. 
Then, DNA target amplified with 200 bp, with VEGF gene 
mutation on allele -460 T/C inside (Figure 2. ) 
 
Figure 2. DNA VEGF allele -460 T/C PCR Product Electrophoresis. Lane 1 : 
marker 2,3,4 and 5 represents sample with 280 bp. 
4.3. NPC Stage Characteristics 
Based on TNM-UICC 2002, we found stage III: 19 
(42.22%), next stage IV (IVA, IVB dan IVC): 14 (31.11%) 
and stage IIB 8 (17.78%). 
4.4. NPC Histopathology Characteristics 
Based on WHO 1979, we found WHO type II: 15 (33.33%) 
and WHO type III: 30 (66.67%) and no WHO type I. 
4.5. Risk Factor 
The risk factor in case group was found that the preserved 
foods, like salted fish, canned food, and smoked meat were 
up to 95.56%, burned woods and mosquito repellent were up 
to 82.22%, smoking was 42.22%, alcohol 33.33%, betel 
chewere 6.67%, Buginese-Makassarese 32 (71.11%) and 
others were 13 (28.89%). 
The risk factor in control group was found that the 
preserved foods, like salted fish, canned food, and smoked 
meat were up to 88.89%, burned woods and mosquito 
repellent were up to 55.56%, smoking was 51.11%, alcohol 
28.89%, betel chewere 11.11%, Buginese-Makassarese 27 
(60.00%) and others were 18 (40.00%). 
4.6. LMP-1 and VEGF-R (Flt-4) Expression 
Immunochemistry tests using avidin-biotin method 
techniques were done in 45 NPC cases biopsy tissues. 
 
Figure 3. LMP-1 and VEGF-R (Flt-4) Expression (Immunochemistry) WHO 
Type III and Stage IV C (A). LMP-1 and VEGF-R (Flt-4) Expression 
(Immunochemistry) WHO Type II and Stage II B (B). 
Positive expression of LMP-1 in nasopharyngeal biopsy 
tissue seems like brownish granula in membran and 
cytoplasm, while in VEGF-R(Flt-4) seems like brownish 
granula in cell cytoplasm (Figure.3). From primary data, we 
found LMP-1 expresion was 42.1%, and VEGF-R (Flt.4) 
100%, there was LMP-1 overexpression (≥ +2) as many as 
13 (28.89%) dan VEGF-R (Flt-4) 19 (42.22%). 
Spearman correlation statistical test for VEGF-R(Flt-4) 
and LMP-1 expressions role against NPC symptomps, consist 
of stage based on TNM-UICC 2002 and histopathology 
characteristic based on WHO 1979, shows no significant 
correlation between stages and VEGF-R (Flt-4) (0.251) and 
LMP-1 (0.257) expressions, that means higher VEGF-R (Flt-
4) and LMP-1 expression in early stage. There is significant 
inverted correlation between histopathology characteristic 
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and VEGF-R (Flt-4) (r = -0.426, p= 0.002) and LMP-1 (r= -
467, p= 0.001) expressions, means VEGF-R (Flt-4) and 
LMP-1 expressions are higher in WHO type II (well 
differentiated) then WHO type III (poorly differentiated). 
There is strong correlation (r= 0.990, p= 0.000) and 
statistically significant between LMP-1 and VEGF-R (Flt-4) 
expression. There is no significant correlation (Spearman) 
(p>0.05) between symptoms, consist of stage and 
histopathology, LMP-1 and VEGF-R (Flt-4) expressions with 
alcohol, smoking, betel chewer, pollutants, and preserved 
foods. 
4.7. VEGF Gene Genotype Distribution 
CG (p= 0.524, OR = -) and GG (p= 0.467, OR = -) 
Genotype within VEGF gene +405 C/G is not found as risk 
factor for NPC incidents. While, Allele C (OR : 0.859) 
against NPC incidents is not statistically significant (p= 
0.696). Non – CC genotype within VEGF gene +405 C/G is 
not found as NPC risk factor. 
 
Figure 4. DNA Sequencing Electroferogram from VEGF allele +405 C/G 
with interchanging base from cytosine (C) to guanine (G). A= Wild type, 
B=Heterozygote and C = homozygote 
 
Figure 5. DNA Sequencing Electroferogram from VEGF allele +405 C/G 
(reverse sequence) with interchanging base from cytosine (C) to guanine (G). 
A= Wild type, B=Heterozygote and C = homozygote 
-460 T/C VEGF genes, TC genotype (p= 0.548, OR = 
0.696; 0.213 – 2.276; 95% CI) and CC (p= 0.581; OR = 
0.648; 0.139-3.036; 95% CI) were not found as risk factor, 
and so as T allele (p= 0.599; OR : 0.809; 0.367-1.785; 95% 
CI), was not statistically significant and the -460 T/C VEGF 
gene Non TT genotype was not found as NPC risk factor. 
 
Figure 6. DNA Sequencing Electroferogram from VEGF allele -460 T/C 
with interchanging base from timine (T) to cytosine (C).. A= Wild type, 
B=Heterozygote and C = homozygote. 
Genetic variation of -457 T/C is a new variant in VEGF 
gene in NPC, and no one has ever reported it. CC genotype is 
more than TC genotype, risk estimation could not defined 
because there was no electroferogram of TT genotype (wild 
type) . 
 
Figure 7. DNA Sequencing Electroferogram from VEGF allele V with 
interchanging base from timine (T) to cytosine (C).. A= Wild type, 
B=Heterozygote and C = homozygote. 
4.8. VEGF Gene +405 C/G and -460 T/C Haplotypes 
There were no GC, CC, GT, and CT haplotypes 
distribution difference in cases and controls group. +405 C/G 
and -460 T/C GC haplotypes have a risk 1.24 times higher to 
suffer NPC, but it is statistically insignificant. +405 C/G and 
-460 T/C haplotypes have 3.21 times higher to suffer NPC 
than CT, but statistically insignificant. Meanwhile, +405 C/G 
and -460 T/C GT haplotypes could not be proved as risk 
factor to suffer NPC and statistically insignificant. 
4.9. Genotypes Distribution, Allele Frequencies, and VEGF 
Gene Haplotypes Relationship with Clinical Symptoms 
(Stages and Histopathology), Expressions (VEGF-R 
(Flt-4) and LMP-1) and Risk Factors 
4.9.1. Mutant Variant with Stages 
It could not be proved about genotypes and allele 
frequencies of VEGF genes +405 C/G (p= 0.815, p= 0.923), -
460 T/C (p= 0.548-0.599) and -457 T/C (p= 0.237, p= 0.269) 
relationship against NPC stages. G allele frequency was 
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higher than C allele in +405 C/G and C allele was higher than 
T allele in -457 T/C, while T allele was higher than C allele 
in -460 T/C against NPC early stages (I-IIA) and late stages 
(IIB-IVC), but it is statistically insignificant. 
4.9.2. Mutant Variant with Histopathology Characteristics 
It could not be proved about genotypes and allele 
frequencies of VEGF genes +405 C/G (p= 0.854, p= 0.924), -
460 T/C (p= 0.509, p= 0.684) and -457 T/C (p= 0.237, p= 
0.268) relationship against NPC histopathology 
characteristics. G allele frequency was higher than C allele in 
+405 C/G, and C allele was higher than T allele in -460 T/C 
and -457 T/C against histopathology characteristic WHO II, 
but statistically insignificant. G allele frequency was higher 
than C allele in +405 C/G in WHO II and III. C allele was 
higher than T allele in -460 T/C in WHO II, but was lower in 
WHO III. C allele -457 T/C frequency was higher in WHO II 
and III, but statistically insignificant. 
4.9.3. Mutant Variant with LMP-1 and VEGF-R (Flt-4) 
Expressions 
It could not be proved about genotypes and allele 
frequencies of VEGF genes +405 C/G (p= 0.927, p= 0.969), -
460 T/C (p= 0.532, p= 0.978) and -457 T/C (p= 0.579, p= 
0.623) relationship against VEGF-R (Flt-4) expressions in 
NPC. G allele frequency was higher than C allele in +405 
C/G, while C allele was higher than T allele in -457 T/C, and 
T allele was higher than C allele in -460 T/C and T allele 
frequency was higher than C allele in -460 T/C against 
VEGF gene VEGF-R(Flt-4) expression, but statistically 
insignificant. 
It could not be proved about genotypes and allele 
frequencies of VEGF genes +405 C/G (p= 0.984, p= 0.980), -
460 T/C (p= 0.698, p= 0.893) and -457 T/C (p= 0.827, p= 
0.839) relationship against VEGF gene LMP-1 expressions in 
NPC. G allele frequency was higher than C allele in +405 
C/G, and C allele was higher than T allele in -457 T/C, and C 
allele frequency was equal with T allele in -460 T/C against 
LMP-1 expression, but it is statistically insignificant. 
4.9.4. Mutant Variant with Risk Factors 
Statistically significant relation could not be proved about 
genotypes and allele frequencies of VEGF genes +405 C/G 
and -457 T/C against betel, pollutants, preserved foods, and 
ethnic group. But there was statistically significant relation 
between genotype and allele frequency in -460 T/C against 
alcohol consumption (p= 0.070) and smoking (p= 0.041). 
Smoking patients with TC genotype variation in VEGF 
gene -460 T/C is 4.3 times higher risk to suffer NPC, and 
statistically significant (p= 0.034). Smoking habit with CC 
genotype in VEGF gene -460 T/C is 7.6 times higher risk to 
suffer NPC, and statistically significant (p= 0.040). Alcohol 
drinker with TC genotype in VEGF gene -460 T/C is 5.6 
times higher risk to suffer NPC, and statistically significant 
(p= 0.025). Alcohol drinker with CC genotype in VEGF gene 
-460 T/C is 2.6 times higher risk to suffer NPC, and 
statistically significant (p= 0.370). 
5. Discussion 
This research was conducted in the form of analyzing 
VEGF gene polymorphism, including genotypes, allele 
frequencies, and +405 C/G and -460 T/C haplotypes against 
clinical symptomps and histopathology in NPC. 
From the sample characteristics, Buginese and 
Makassarese ethnic groups is the most group suffering NPC 
in Makassar 32 (71.11%), similarly to a study conducted in 
Makassar in 1997.
3
 But it does not represent actual 
characteristic because Chinese ethnic group was not 
represented in this study, which is the highest incidence in 
the world.
16
 The age group mean is 45.80 ± 13.70, means it 
was in productive age. Male are 38 (84.44%) dan female 
were 7 (15.56%), with ratio 5 : 1, is higher than the previous 
study which is 2-3 : 1 and it is probably caused by the 
smaller samples than before.
1, 6, 12
 Primary complaint in NPC 
patient in this study was epistaxis with 16 patients (35.56%), 
then cephalgia were 9 patients (20%). The most chief 
complaint is superolateral neck mass by 24 patients (53.33%), 
then nasal obstruction with 10 patients (22.22%), and there 
are untypical symptomps, like tinnitus, aural fullness, 
unilateral hearing loss in the early stages; different with the 
past study, there are only two primary complaint, the neck 
mass and nasal obstruction.
3, 17
 It means flu like symptomps 
with bloodstained discharge and chronic cephalgia, tinnitus 
or unilateral conductive hearing loss must be suspected as a 
malignancy until is proven not a malignancy from complete 
ENT examination. Chief complaints in this study are the 
same from past study, that are neck mass and nasal 
obstruction. It means, there is no changing from patients 
awareness to have an early ENT examination or 
misdiagnosed in the primary health care. 
Based on TNM-UICC 2002 stages, stage III 19 (42.22%) 
then stage IV (IVA, IVB and IVC) 14 (31.11%) and stage IIB 
8 (17.78%), there are no difference from the past study.
2, 3, 4, 
17
 Based on WHO 1979 histopathology, WHO type III 30 
(66.67%), type II 15 (33.33%) and no WHO type I, same as 
the report that by Fransisca and Perkasa, but it is different 
from Xie K. that even WHO type III is the most, they found 
WHO type I in North America up to 25%, in South China is 
2%.
17, 18, 19
 Khabir et al. reported the WHO type I as many as 
1.2 % in North Africa, with WHO type II and III nearly 
100%, that WHO type III is 100% correlated with EBV 
infection.
16, 20, 21
 It means, the NPC incidence in Makassar is 
well correlated with EBV infection. Thus, diagnostic, 
prognostic, and therapeutic efforts are focused to molecular 
biology approach against EBV. 
In this study, VEGF-R (Flt-4) and LMP-1 expressions 
from biopsy tissues with immunochemistry test with avidin 
biotin method technique is found positive expression of 
LMP-1 in nasopharyngeal biopsy tissue seems like brownish 
granula in membran and cytoplasm, while in VEGF-R (Flt-4) 
seems like brownish granula in cell cytoplasm. We found 
LMP-1 expresion was 42.1%, lower from the study by 
Khabir A et al. with 60% and VEGF-R (Flt.4) 100%, same 
with the result by Soo R et al. and higher from Liu XF et al. 
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that is 61.25%.
15, 22, 23
 From LMP-1 overexpression (≥ +2) as 
many as 13 (28.89%) dan VEGF-R (Flt-4) are 19 (42.22%), 
it means not all the NPC express LMP-1, even in EBV 
infected epithelial cell and actively replicating.
24
 Based on 
that statement, it is needed to find another oncoproteins 
alternative as a biomarker beside LMP-1, for more accute 
diagnostic and prognostic consideration. 
VEGF-R (Flt-4) is a receptor from VEGF-C and very 
important in angiogenesis and lymphangiogenesis, it means 
there is a regional metastatic potential to lymph nodes is high. 
This can explain that neck mass is still the chief complaint in 
NPC patients in Makassar. 
Spearman correlation statistical test result for VEGF-R 
(Flt-4) and LMP-1 expressions role against NPC symptomps, 
consist of stage based on TNM-UICC 2002 and 
histopathology characteristic based on WHO 1979, shows no 
significant correlation (p>0.05) between stages and VEGF-R 
(Flt-4) (0.257) and LMP-1 (0.251) expressions, that means, 
higher VEGF-R (Flt-4) and LMP-1 are expressed in early 
stage. It means VEGF-R (Flt-4) and LMP-1 probably has a 
role in early stage NPC carcinogenesis, similiar to Bcl-2 
(Homolog) role in Colorectal carcinoma.
25 
There is no significant correlation between symptoms, 
consists of stage and histopathology, LMP-1 and VEGF-R 
(Flt-4) expressions, with alcohol, smoking, betel chewer, 
pollutants, and preserved foods in NPC. There is a strong 
correlation between LMP-1 and VEGF-R (Flt-4) expression 
in NPC, it means the higher LMP-1 expression and VEGF-R 
(Flt-4) expression is higher too. Thus, LMP-1 is a important 
regulator (Up-regulator) of VEGF-R (Flt-4) and has a 
angiogenic potential as a pleiotropic character from LMP-1 
beside from transcription activation, gene expression, and 
cell transformation, cell growth and death.
11, 26 
Sequence variation from VEGF gene could affect VEGF 
production and activity that causing susceptibillity difference 
between individuals against various of disease like lung 
carcinoma (squamous cell carcinoma), but from this study in 
NPC, we found CG, GG and C allele in VEGF gene +460 
C/G, it could not prove as a risk factor for NPC incidence in 
Makassar. Furthermore, new mutant variation in -457 T/C 
that have not been reported before with TC, CC genotypes 
and T allele could not be proven as a risk factor for NPC in 
Makassar. It caused by there was no electroferogram result of 
TT genotype as a base of wild-type homozygot allele, and 
complicates the evaluation of genotype distribution and allele 
frequency. 
Non-CC genotype VEGF gene +405 C/G, which in the 
case of 94.44%, 97.14% controls (OR = 0.971; 95% CI; 0.58 
to 16.163) and non-TT genotype -460 T/C in the case of 
78.12%, 70.97% controls (OR = 0.684; 95% CI; 0.218 to 
2.144) has not been proven as risk factors of NPC in 
Makassar. The frequency of non CC +405 C/G and non -TT -
460 T/C equal those found by Lee S. J. in squamous cell 
carcinoma of the lung.
13
 This means that non-CC and non-TT 
which is a form of polymorphism +405 C/G and -460 T/C 
(frequency of more than 1%), as reported by Steven A et al. 
found as much as 67.50% in breast and endometrial cells in 
the UK, Prats AC et al. found 40% of the population of 
diabetic retinopathy in Japanese, while Lee SJ et al. found in 
lung squamous cell carcinoma of 55.70% in Korea.
13, 14, 27
 
Therefore, highly polymorphic VEGF gene especially at 
positions +405 C/G and -460 T/C as well as the -457 T/C 
which is a variant of a new mutation that has not been 
previously reported. It is also no reports of VEGF gene allele 
polymorphism +405 C/G and -460 T/C on the NPC until we 
made this study. 
Haplotype GC and CC at VEGF gene +405 C/G and -460 
T/C at risk of suffering from NPC compared to CT, although 
it is not statistically significant, while the GT haplotype at 
VEGF gene +405 C/G and -460 T/C at risk NPC suffer than 
CT but was not statistically significant. Compared to the 
results of the studies on breast cells, endometrial and lung 
squamous cell carcinoma before, is seen a higher frequency 
of mutations in the variant allele +405 C/G than -460 T/C, as 
obtained in this study. This means that the allele +405 C/G is 
a hot spot of VEGF gene. This explains the genetic variants 
of VEGF are a form of VEGF gene polymorphisms in the 
promoter region of high.
14 
In the NPC early stage (I - IIA) or advanced (IIB - IVC) 
turns the G allele frequency was higher than the C allele at 
+405 C/G, allele C higher than T at -457 T/C and T alleles 
more higher than the C allele at VEGF gene -460 T/C in NPC 
patients in Makassar, although it is not statistically significant. 
So the G allele has a role in the early and advanced stages of 
NPC, although it is not statistically significant, but still 
requires further study with a larger sample size. 
There were no relationships between genotype distribution 
and allele frequencies at VEGF gene +405 C/G, -460 T/C and 
-457 T/C with the NPC risk factors in Makassar, except in 
person with a variety of TC and CC genotypes VEGF gene -
460 T/C with smoking habit 4.3 and 7.6 times likely to suffer 
from NPC earlier than nonsmokers, and it is statistically 
significant. Person with TC and CC genotypes variation 
VEGF gene -460 T/C with alcohol drinking habits of 5.6 and 
2.6 times likely to suffer from NPC than non drinking 
alcohol. From the viewed of genotype TC, CC and allele T at 
-460 T/C without smoking or alcohol compared to those with 
the habit of smoking or drinking alcohol on the risk of 
suffering from NPC, it was obvious the interaction of genetic 
and environmental on the incidence of NPC. That is 
phenotypically expression of VEGF gene in the -460 T/C on 
the NPC is influenced by environmental factors. 
Nasopharyngeal carcinoma is still the most common 
malignancy in head and neck in Indonesia. Buginese and 
Makassarese ethnic groups are still the most group suffering 
NPC in Makassar with primary complaint and most of the 
chief complaint is superolateral neck mass, which caused by 
VEGF-R(Flt-4) overexpression, which is a receptor from 
VEGF-C, that is an important in angiogenesis and 
lymphangiogenesis; therefore, has a high potential to regional 
metastatic of lymphnodes, nasal obstruction, and untypical 
symptomps, like tinnitus, aural fullness, and unilateral 
hearing loss in earlier stage, which can be misdiagnosed in 
the primary healthcare. We found most of them seek 
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healtcare in stage III, that has lower survival rates and poor 
prognosis. Means, we need to achieve preventive effort, like 
health promotion and education for NPC, where smoking and 
drinking alcohol are still a risk factor for NPC. Furthermore, 
NPC management needs an intergrated and holistic 
evaluation with multidiscipline approach that involve public 
and private society. 
Sequence variation from VEGF gene could affect VEGF 
production and activity that causing susceptibillity difference 
between individuals against various of disease like lung 
carcinoma (squamous cell carcinoma), but from this study in 
NPC, we could not prove it as a risk factor for NPC 
incidence in Makassar. And, new mutant variation in -457 
T/C that have not been reported before with TC, CC 
genotypes and T allele could not be prove as a risk factor for 
NPC in Makassar and non-CC genotype VEGF gene +405 C 
/ G, and non-TT genotype -460 T / C has not been prove too 
as risk factors of NPC in Makassar. 
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